TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/11/2024
Voltar para busca
Dado oficial do USPTO
VERAXA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
VERAXA
ST13
US500000090784943Classe
1, 5, 9, 10, 42, 44
Pedido
90784943
Registro
7282793
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
13/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9, 10, 42, 44
Data de depósito
21/06/2021
Data de registro
23/01/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/01/2024
Última transação
13/11/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
27
Localização do titular
HEIDELBERG, DE
Examinador
TARABAN, LAURA KRISTEN
Unidade examinadora
N90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
VERAXA BIOTECH GMBH
Velabs Therapeutics GmbH
Representantes
Michael J. Leonard Fox Rothschild LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Antibodies and the chemical modifications and conjugates thereof for medical research purposes and medical laboratory tests for medical research purposes; Immunoglobulins for medical research use; Structural proteins in the nature of proteins in raw material form and protein arrays for medical research purposes
Classe 5
Antibodies and the chemical modifications and conjugates thereof for medical diagnosis and treatment purposes and medical laboratory tests for medical diagnosis and treatment purposes; Immunoglobulins for medical use for the treatment and prevention of disease; Vaccines; Structural proteins in the nature of proteins in raw material form and protein arrays for medical diagnosis and treatment purposes; Veterinary preparationsanti-cancer medicationanti-inflammatory medicationanti-pain medication in creampowdertablet and injectable form; Medical preparationsdiagnostic preparationstherapeutic preparations for medical use in the nature of anti-cancer medicationanti-inflammatory medicationanti-pain medication in creampowdertablet and injectable form; Pharmaceutical preparationsanti-cancer preparationsanti-inflammatory preparationsanti-pain preparationsmetabolic preparations for treating diabetes and obesity in creampowdertabletinjectable form
Classe 9
Opto-electronic apparatus and instruments and downloadable and recorded computer software and microfluid chips for conducting antibodypeptide or high-throughput active agent search with small inorganic or organic molecules for scientific research purposes
Classe 10
Medical opto-electronic apparatus and instruments for conducting antibodypeptide or high-throughput active agent search with small inorganic or organic molecules for medical diagnosis and treatment purposes
Classe 42
Scientific research conducted using high-throughput active agent search and bioinformatics methods; Drug discovery services; Research and testing services in the field of antibody active agent search services for scientific research purposes; Researchtestingdevelopment services in the field of antibody modification and conjugate services for scientific research purposes; Research and testing services in the field of vaccine search services for scientific research purposes
Classe 44
Medical services; Medical diagnosis testsmonitoring and reporting and medical screening services in the nature of medical active agent search services; Medical screening services in the nature of medical combing and medical active agent search of antibodies originating from patients; Personal medical information services
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
13/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/11/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
13/11/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
13/11/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/01/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
23/01/2024
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
14/12/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
14/12/2023
IUCN
NOTICE OF ALLOWANCE CANCELLED
15/11/2023
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
15/11/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
14/11/2023
TMBN
TTAB RELEASE CASE TO TRADEMARKS
02/10/2023
OP.T
OPPOSITION TERMINATED NO. 999999
02/10/2023
OP.D
OPPOSITION DISMISSED NO. 999999
02/10/2023
OP.I
OPPOSITION INSTITUTED NO. 999999
21/08/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
23/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/02/2023
PUBO
PUBLISHED FOR OPPOSITION
21/02/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/01/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
17/01/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
17/01/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
17/01/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
17/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/12/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/10/2022
GNRT
NON-FINAL ACTION E-MAILED
03/10/2022
CNRT
NON-FINAL ACTION WRITTEN
03/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/08/2022
ALIE
ASSIGNED TO LIE
25/08/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/04/2022
GNRT
NON-FINAL ACTION E-MAILED
02/04/2022
CNRT
NON-FINAL ACTION WRITTEN
02/04/2022
DOCK
ASSIGNED TO EXAMINER
11/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/09/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
21/07/2021
NWAP
NEW APPLICATION ENTERED
24/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VERAXA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.